Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial.
Heikki Joensuu(Orion Corporation (Finland)), Henrik Lindman(Uppsala University), Paula Poikonen‐Saksela(Turku University Hospital), Arja Jukkola‐Vuorinen(University of Oulu), Päivi Auvinen(University of Eastern Finland), Minna Tanner(Tampere University Hospital), Paul Nyandoto(Päijät-Hämeen Keskussairaala), Outi Lahdenperä(Turku University Hospital), Vesa Kataja(Kuopio University Hospital), Riikka Huovinen(Turku University Hospital), Marja Murashev(Satakunta Central Hospital), Greger Nilsson(Turku University Hospital), Pirkko‐Liisa Kellokumpu‐Lehtinen, Petri Bono(Helsinki University Hospital), Kenneth Villman(Örebro University Hospital), R. Kokko
Cited by 10
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k